Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lyrica Scheduling Decision Expected In Second Quarter; Launch To Follow

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer hopes to complete the DEA scheduling process for Lyrica during the second quarter, clearing the way for the launch of the neuropathic pain agent

You may also be interested in...



NeurogesX Reports Successful Phase III Trial For NGX-4010 In Post-Herpetic Neuralgia

Firm plans to file with EMEA for peripheral neuropathic pain indication later this year.

NeurogesX Reports Successful Phase III Trial For NGX-4010 In Post-Herpetic Neuralgia

Firm plans to file with EMEA for peripheral neuropathic pain indication later this year.

Pfizer’s Lyrica: DEA Proposes Schedule V Designation, Comments Due June 13

The pregabalin launch is at least a month away following the Drug Enforcement Administration’s proposed rule on controlled substance scheduling for the neuropathic pain agent. Lyrica has a “low potential for abuse” relative to Schedule IV substances, DEA says.

Topics

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel